| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $11,367,155 | 31 | 100 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 0 | $0 | 11 | $212,215 | $-212,215 |
| Davis Krista | SVP, CHIEF HR OFFICER | 0 | $0 | 4 | $302,350 | $-302,350 |
| Gutwerg Ori | SVP, GENERICS | 0 | $0 | 2 | $375,971 | $-375,971 |
| CAREY STEPHEN P. | SVP & CFO | 0 | $0 | 1 | $418,425 | $-418,425 |
| Mutz Christopher | HEAD OF RARE DISEASE | 0 | $0 | 2 | $616,850 | $-616,850 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 0 | $0 | 1 | $1.27M | $-1.27M |
| Lalwani Nikhil | PRESIDENT & CEO | 0 | $0 | 1 | $1.94M | $-1.94M |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 0 | $0 | 9 | $6.23M | $-6.23M |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Over the last 12 months, insiders at ANI Pharmaceuticals, Inc. have bought $0 and sold $11.37M worth of ANI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ANI Pharmaceuticals, Inc. have bought $730,297 and sold $30.53M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $138,794 was made by Walsh Patrick D () on 2022‑03‑21.
| 2025-05-15 | Sale | Gutwerg Ori | SVP, GENERICS | 881 0.0041% | $60.07 | $52,922 | -0.00% | |
| 2025-05-14 | Sale | Mutz Christopher | HEAD OF RARE DISEASE | 4,000 0.0185% | $60.45 | $241,800 | -1.52% | |
| 2025-05-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $62.20 | $24,880 | -1.33% | |
| 2025-05-09 | Sale | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 700 0.0038% | $76.83 | $53,781 | -13.73% | |
| 2025-04-14 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $68.96 | $27,584 | -8.05% | |
| 2025-03-19 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,866 0.0086% | $65.00 | $121,290 | +2.00% | |
| 2025-03-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $63.33 | $25,332 | +6.65% | |
| 2025-03-07 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,000 0.0046% | $60.86 | $60,860 | +6.58% | |
| 2025-03-05 | Sale | Gutwerg Ori | SVP, GENERICS | 5,384 0.0248% | $60.00 | $323,049 | +7.83% | |
| 2025-02-21 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,000 0.0048% | $60.20 | $60,200 | +9.98% | |
| 2025-02-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $59.54 | $23,816 | +6.88% | |
| 2025-01-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $53.92 | $21,568 | +13.20% | |
| 2024-12-17 | Sale | CAREY STEPHEN P. | SVP & CFO | 7,500 0.0358% | $55.79 | $418,425 | +7.93% | |
| 2024-12-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $56.24 | $14,060 | +6.36% | |
| 2024-12-11 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,000 0.0048% | $60.00 | $60,000 | +1.61% | |
| 2024-11-26 | Sale | Lalwani Nikhil | PRESIDENT & CEO | 33,481 0.1592% | $57.99 | $1.94M | +3.15% | |
| 2024-11-15 | Sale | Mutz Christopher | HEAD OF RARE DISEASE | 6,500 0.0304% | $57.70 | $375,050 | +5.36% | |
| 2024-11-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $61.36 | $15,340 | -0.43% | |
| 2024-10-14 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $57.19 | $14,298 | +1.49% | |
| 2024-09-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $56.82 | $14,205 | +1.16% |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 631920 2.9187% | $39.53M | 1 | 57 | +24.75% |
| Lalwani Nikhil | PRESIDENT & CEO | 370378 1.7107% | $23.17M | 1 | 6 | +31.46% |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 193226 0.8925% | $12.09M | 1 | 10 | +29.72% |
| CAREY STEPHEN P. | SVP & CFO | 154468 0.7134% | $9.66M | 0 | 4 | |
| Mutz Christopher | HEAD OF RARE DISEASE | 107317 0.4957% | $6.71M | 0 | 5 | |
| Gutwerg Ori | SVP, GENERICS | 89897 0.4152% | $5.62M | 0 | 4 | |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 79745 0.3683% | $4.99M | 0 | 18 | |
| Davis Krista | SVP, CHIEF HR OFFICER | 64659 0.2986% | $4.05M | 0 | 5 | |
| MERIDIAN VENTURE PARTNERS II LP | 10 percent owner | 1819259 8.4026% | $113.81M | 0 | 18 | |
| MORGENSTERN VICTOR A | director | 455571 2.1041% | $28.5M | 2 | 0 | +243.13% |
| MARSHBANKS TRACY | director | 349934 1.6162% | $21.89M | 0 | 16 | |
| RAYNOR DANIEL | director | 289003 1.3348% | $18.08M | 0 | 8 | |
| EDELMAN JOSEPH | 10 percent owner | 209100 0.9658% | $13.08M | 23 | 7 | <0.0001% |
| PRZYBYL ARTHUR | President and CEO | 202589 0.9357% | $12.67M | 2 | 10 | +64.77% |
| SIMES STEPHEN M | Vice Chairman, President & CEO | 202167 0.9337% | $12.65M | 4 | 1 | +6.23% |
| Marken James G. | SVP OPS & PROD DEV | 124492 0.575% | $7.79M | 0 | 9 | |
| HOLUBOW FRED | director | 61259 0.2829% | $3.83M | 1 | 2 | |
| Schrepfer Robert W | SVP - New Bus Dev & Spec Sales | 55927 0.2583% | $3.5M | 0 | 5 | |
| Walsh Patrick D | 53388 0.2466% | $3.34M | 4 | 0 | +15.33% | |
| SULLIVAN LOUIS W | director | 47898 0.2212% | $3M | 2 | 0 | |
| DONENBERG PHILIP B | Sr. VP of Finance, CFO & Secy | 44322 0.2047% | $2.77M | 8 | 0 | +32.33% |
| KJAER PETER | director | 34425 0.159% | $2.15M | 2 | 0 | +3.25% |
| HAUGHEY THOMAS | director | 30202 0.1395% | $1.89M | 4 | 0 | <0.0001% |
| MANGANO ROSS J | director | 26914 0.1243% | $1.68M | 19 | 0 | +73.75% |
| Pera Antonio R | director | 26627 0.123% | $1.67M | 1 | 2 | <0.0001% |
| Arnold Charlotte C. | Vice President and CFO | 21385 0.0988% | $1.34M | 0 | 1 | |
| ROSENOW EDWARD C III | director | 20540 0.0949% | $1.28M | 1 | 0 | |
| TANNENBAUM RENEE P | director | 18211 0.0841% | $1.14M | 0 | 1 | |
| Thoma Jeanne | director | 17785 0.0821% | $1.11M | 1 | 0 | <0.0001% |
| NASH DAVID | director | 5236 0.0242% | $327,564.16 | 1 | 0 | <0.0001% |
| BELL STEVEN J | VP Research & Pre-Clinical Dev | 875 0.004% | $54,740.00 | 0 | 9 | |
| LEHMAN LEAH M | VP, Product Development | 0 0% | $0 | 1 | 5 |
$910,099,463 | 123 | 11.52% | $2.21B | |
$187,390,806 | 89 | 12.62% | $826.9M | |
$12,681,496 | 70 | 20.90% | $925.79M | |
ANI Pharmaceuticals, Inc. (ANIP) | $14,599,168 | 59 | 12.79% | $1.35B |
$23,522,750 | 59 | -6.74% | $6.86B | |
$11,542,910 | 40 | 56.19% | $1.11B | |
$102,493,771 | 40 | 22.98% | $1.12B | |
$21,020,549 | 38 | -2.84% | $12.31B | |
$73,284,153 | 37 | -4.48% | $3.66B | |
$21,068,600 | 35 | 9.64% | $1.23B | |
$12,998,723 | 30 | 3.46% | $3.61B | |
$6,506,230 | 27 | -16.20% | $743.86M | |
$83,406,412 | 19 | 21.96% | $1.79B | |
$2,233,486 | 16 | -3.32% | $10.47B | |
$1,843,996 | 10 | 22.92% | $1.22B | |
$26,633,903 | 9 | 42.23% | $937.91M | |
$141,200 | 8 | 41.74% | $5.38B | |
$32,954,224 | 5 | -0.22% | $19.47B | |
$514,533 | 5 | 29.61% | $969.97M |
| Increased Positions | 112 | +47.26% | 3M | +13.51% |
| Decreased Positions | 95 | -40.08% | 2M | -10.22% |
| New Positions | 47 | New | 936,586 | New |
| Sold Out Positions | 23 | Sold Out | 259,298 | Sold Out |
| Total Postitions | 254 | +7.17% | 20M | +3.29% |
| Blackrock, Inc. | $193,072.00 | 12.03% | 2.65M | -91,942 | -3.36% | 2025-03-31 |
| Vanguard Group Inc | $95,883.00 | 5.97% | 1.31M | -33,739 | -2.5% | 2024-12-31 |
| Millennium Management Llc | $73,158.00 | 4.56% | 1M | +473,097 | +89.31% | 2024-12-31 |
| State Street Corp | $53,785.00 | 3.35% | 737,288 | +33,445 | +4.75% | 2024-12-31 |
| Goldman Sachs Group Inc | $51,037.00 | 3.18% | 699,618 | -16,451 | -2.3% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $50,024.00 | 3.12% | 685,730 | +30,420 | +4.64% | 2024-12-31 |
| Deep Track Capital, Lp | $47,348.00 | 2.95% | 649,042 | +144,214 | +28.57% | 2024-12-31 |
| Global Alpha Capital Management Ltd. | $45,561.00 | 2.84% | 624,550 | +88,100 | +16.42% | 2024-12-31 |
| Ubs Group Ag | $43,391.00 | 2.7% | 594,810 | +308,322 | +107.62% | 2024-12-31 |
| Citadel Advisors Llc | $43,157.00 | 2.69% | 591,594 | +61,717 | +11.65% | 2024-12-31 |